Global /United States /Healthcare /Biotechnology /KLRS

Kalaris Therapeutics, Inc.

KLRS

• NASDAQ: KLRS • Delayed

5.47USD -2.9%

As of 14 June 2026, Kalaris Therapeutics, Inc. has a market cap of $125.42M USD, ranking #24016 globally and #3763 in the United States. It ranks #2154 in the Healthcare sector, and #414 in the Biotechnology industry.

Global Rank

24016

Country Rank

3763

Sector Rank

2154

Industry Rank

414

Key Stats

Market Cap

$125.42MUSD

Enterprise Value

$11.64MUSD

EBITDA (TTM)

-$46.14MUSD

Net Income (TTM)

-$43.44MUSD

PB Ratio

1.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Andrew Oxtoby open_in_new

Employees

Founded

2019

Website

kalaristx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.9%	-14%	1.5%	-42%	9.4%	-35%	-18%	-100%	-100%

News

KLRS Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	KLRS Kalaris Therapeutics Inc ISIN: US4829291065 Shares Out.: Shares Outstanding: 23.792M¹ Shares Float: 8.476M² TV: TradingView: NASDAQ: KLRS SA: Stock Analysis: NASDAQ: KLRS YF: Yahoo Finance: KLRS GF: Google Finance: NASDAQ: KLRS NQ: NASDAQ: KLRS BA: Barron's: KLRS MS: Morningstar: XNAS: KLRS	5.47 USD	TV: TradingView: NASDAQ: KLRS SA: Stock Analysis: NASDAQ: KLRS YF: Yahoo Finance: KLRS GF: Google Finance: NASDAQ: KLRS NQ: NASDAQ: KLRS BA: Barron's: KLRS MS: Morningstar: XNAS: KLRS

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 145K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 127K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 22K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 21K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 20K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 14K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 38K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 36K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 34K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 34K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 22K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 20K%	-	Germany

chevron_leftBack